| 3E06002 | Introduction of High-dose Interleukin-2 into Central Artery, Open Approach |
| 3E06003 | Introduction of Low-dose Interleukin-2 into Central Artery, Open Approach |
| 3E06005 | Introduction of Other Antineoplastic into Central Artery, Open Approach |
| 3E0600M | Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Open Approach |
| 3E0600P | Introduction of Clofarabine into Central Artery, Open Approach |
| 3E06016 | Introduction of Recombinant Human-activated Protein C into Central Artery, Open |
| 3E06017 | Introduction of Other Thrombolytic into Central Artery, Open Approach |
| 3E06028 | Introduction of Oxazolidinones into Central Artery, Open Approach |
| 3E06029 | Introduction of Other Anti-infective into Central Artery, Open Approach |
| 3E0603Z | Introduction of Anti-inflammatory into Central Artery, Open Approach |
| 3E0604Z | Introduction of Serum, Toxoid and Vaccine into Central Artery, Open Approach |
| 3E0606Z | Introduction of Nutritional Substance into Central Artery, Open Approach |
| 3E0607Z | Introduction of Electrolytic and Water Balance Substance into Central Artery, Open Approach |
| 3E060FZ | Introduction of Intracirculatory Anesthetic into Central Artery, Open Approach |
| 3E060GC | Introduction of Other Therapeutic Substance into Central Artery, Open Approach |
| 3E060GN | Introduction of Blood Brain Barrier Disruption Substance into Central Artery, Open Approach |
| 3E060HZ | Introduction of Radioactive Substance into Central Artery, Open Approach |
| 3E060KZ | Introduction of Other Diagnostic Substance into Central Artery, Open Approach |
| 3E060NZ | Introduction of Analgesics, Hypnotics, Sedatives into Central Artery, Open Approach |
| 3E060PZ | Introduction of Platelet Inhibitor into Central Artery, Open Approach |
| 3E060RZ | Introduction of Antiarrhythmic into Central Artery, Open Approach |
| 3E060TZ | Introduction of Destructive Agent into Central Artery, Open Approach |
| 3E060VG | Introduction of Insulin into Central Artery, Open Approach |
| 3E060VH | Introduction of Human B-type Natriuretic Peptide into Central Artery, Open Approach |
| 3E060VJ | Introduction of Other Hormone into Central Artery, Open Approach |
| 3E060WK | Introduction of Immunostimulator into Central Artery, Open |
| 3E060WL | Introduction of Immunosuppressive into Central Artery, Open |
| 3E060XZ | Introduction of Vasopressor into Central Artery, Open Approach |
| 3E06302 | Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach |
| 3E06303 | Introduction of Low-dose Interleukin-2 into Central Artery, Percutaneous Approach |
| 3E06305 | Introduction of Other Antineoplastic into Central Artery, Percutaneous Approach |
| 3E0630M | Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Percutaneous Approach |
| 3E0630P | Introduction of Clofarabine into Central Artery, Percutaneous Approach |
| 3E06316 | Introduction of Recombinant Human-activated Protein C into Central Artery, Percutaneous |
| 3E06328 | Introduction of Oxazolidinones into Central Artery, Percutaneous Approach |
| 3E06329 | Introduction of Other Anti-infective into Central Artery, Percutaneous Approach |
| 3E0633Z | Introduction of Anti-inflammatory into Central Artery, Percutaneous Approach |
| 3E0634Z | Introduction of Serum, Toxoid and Vaccine into Central Artery, Percutaneous Approach |
| 3E0636Z | Introduction of Nutritional Substance into Central Artery, Percutaneous Approach |
| 3E0637Z | Introduction of Electrolytic and Water Balance Substance into Central Artery, Percutaneous Approach |
| 3E063FZ | Introduction of Intracirculatory Anesthetic into Central Artery, Percutaneous Approach |
| 3E063GC | Introduction of Other Therapeutic Substance into Central Artery, Percutaneous Approach |
| 3E063GN | Introduction of Blood Brain Barrier Disruption Substance into Central Artery, Percutaneous Approach |
| 3E063HZ | Introduction of Radioactive Substance into Central Artery, Percutaneous Approach |
| 3E063KZ | Introduction of Other Diagnostic Substance into Central Artery, Percutaneous Approach |
| 3E063NZ | Introduction of Analgesics, Hypnotics, Sedatives into Central Artery, Percutaneous Approach |
| 3E063PZ | Introduction of Platelet Inhibitor into Central Artery, Percutaneous Approach |
| 3E063RZ | Introduction of Antiarrhythmic into Central Artery, Percutaneous Approach |
| 3E063TZ | Introduction of Destructive Agent into Central Artery, Percutaneous Approach |
| 3E063VG | Introduction of Insulin into Central Artery, Percutaneous Approach |
| 3E063VH | Introduction of Human B-type Natriuretic Peptide into Central Artery, Percutaneous Approach |
| 3E063VJ | Introduction of Other Hormone into Central Artery, Percutaneous Approach |
| 3E063WK | Introduction of Immunostimulator into Central Artery, Percutaneous |
| 3E063WL | Introduction of Immunosuppressive into Central Artery, Percutaneous |
| 3E063XZ | Introduction of Vasopressor into Central Artery, Percutaneous Approach |
